介乐-6:心房动中的分子机制和治疗前景
Jin-Fang Yu1,2,3,4,5, Qian Dong1,2,3,4,5, Yi-Mei Du6,7,8,9,10
1Department of Cardiology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430022, China.
Current medical science
|March 4, 2025
概括
介乐-6 (IL-6) 通过炎症和重塑驱动心房动 (AF). 阻断IL-6可能为管理这种常见的心律障碍提供了一个新的治疗策略.
科学领域:
- 心脏病学 心脏病学
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
背景情况:
- 心房动 (AF) 是一种广泛的心律失常,与复杂的心房重塑有关.
- 升高的IL-6水平与AF的发病和进展密切相关.
研究的目的:
- 审查IL-6对AF的贡献机制.
- 评估IL-6作为AF的潜在治疗点.
主要方法:
- 文献综述侧重于炎症途径,心房纤维化,电力改造和AF中的处理.
- 对研究IL-6在AF中的作用的实验模型的分析.
主要成果:
- IL-6通过炎症,纤维化和电气/失调促进AF.
- 实验IL-6中和降低了AF发生率.
结论:
- IL-6在AF的发展和维护中发挥着重要作用.
- 准IL-6阻塞为AF管理提供了一个有前途的治疗途径.
相关概念视频
Intracellular Signaling Affects Focal Adhesions
2.5K
Integrins act both as extracellular input receivers and as intracellular processing activators. As their name suggests, integrins are entirely integrated into the membrane structure. Their hydrophobic membrane-spanning regions interact with the phospholipid bilayer's hydrophobic region. These membrane receptors provide extracellular attachment sites for effectors like hormones and growth factors. They activate intracellular response cascades when their effectors are bound and active.
Some...
Some...
2.5K
The JAK-STAT Signaling Pathway
8.6K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.6K
Anticoagulant Drugs: Low-Molecular-Weight Heparins
590
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
590
Clot Retraction and Fibrinolysis
3.3K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
3.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
363
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
363
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.1K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.1K


